Temel İstatistikler
| LEI | 549300DJ0Q0D9TVY5O19 |
| CIK | 1585608 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Jaguar Health, Inc.
SEC Filings (Chronological Order)
Bu sayfa, başka bir yerde sunduğumuz mülkiyet başvuruları hariç, SEC Dosyalarının tam ve kronolojik bir listesini sunmaktadır.
| June 2, 2026 |
EX-10.1 Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 26, 2026 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liablity company (“Lender”), and Jaguar Health, Inc., a Delaw |
|
| June 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 2, 2026 |
EX-10.2 Exhibit 10.2 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of June 1, 2026 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liablity company (“Lender”), and Jaguar Health, Inc., a Delaw |
|
| May 29, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 27, 2026 |
EX-99.1 Exhibit 99.1 Jaguar Health Compliant with Nasdaq Bid Price Rule JAGX’s securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / May 27, 2026 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that Jaguar has regained compliance with Nasdaq List |
|
| May 22, 2026 |
EX-10.2 Exhibit 10.2 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 21, 2026 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liablity company (“Lender”), and Jaguar Health, Inc., a Delaw |
|
| May 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 22, 2026 |
EX-10.1 Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 21, 2026 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liablity company (“Lender”), and Jaguar Health, Inc., a Delaw |
|
| May 20, 2026 |
EX-99.1 Exhibit 99.1 Jaguar Health Reports First Quarter 2026 Financials Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi® and Canalevia®-CA1 Company continues its focus on crofelemer development efforts for rare-disease intestinal failure indications; two crofelemer presentations in pediatric intes |
|
| May 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 20, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 19, 2026 |
EX-10.1 Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 19, 2026 (the “Effective Date”) by and between Uptown Capital, LLC, a Utah limited partnership (f/k/a Irving Park Capital, LLC) (“Investor”), and Jagua |
|
| May 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 19, 2026 |
EX-10.2 Exhibit 10.2 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 19, 2026 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc., a De |
|
| May 19, 2026 |
EX-3.1 Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES Q PERPETUAL PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of Jaguar |
|
| May 19, 2026 |
EX-10.3 Exhibit 10.3 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 19, 2026 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc., a De |
|
| May 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36714 CUSIP NUMBER 47010C 862 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2026 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 6, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| April 30, 2026 |
200 Pine Street, Suite 400, San Francisco, CA 94104 Tel: 415.371.8300 • Fax: 415.371.8311 https://jaguar.health April 29, 2026 Dear Stockholder: You are cordially invited to attend the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Jaguar Health, Inc. (the “Company”) to be held at 200 Pine Street, Suite 400, San Francisco, CA 94104, on Friday, May 22, 2026, at 8:30 a.m., local time. |
|
| April 27, 2026 |
EX-99.1 Exhibit 99.1 Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq’s Bid Price Rule; Company Announces Reverse Stock Split Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on April 30, 2026 San Francisco, CA (April 27, 2026): Jaguar Health, Inc. (Nasdaq: JAG |
|
| April 27, 2026 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF ELEVENTH AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JAGUAR HEALTH, INC. Jaguar Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that: 1. The name of the Corporation is Jaguar Health, Inc. The date of filing of the Corporation’s original Certificate of I |
|
| April 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 21, 2026 |
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders EX-99.1 Exhibit 99.1 Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders San Francisco, CA (April 20, 2026): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced the voting results of the Company’s Special Meeting of Stockholders held on April 20, 2026 (the “Special Meeting”). Five proposals were submitted to and approved by the s |
|
| April 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 21, 2026 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF TENTH AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JAGUAR HEALTH, INC. Jaguar Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that: 1. The name of the Corporation is Jaguar Health, Inc. The date of filing of the Corporation’s original Certificate of Inc |
|
| April 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| April 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 7, 2026 |
THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| April 7, 2026 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT JAGUAR HEALTH, INC. PRE-FUNDED COMMON STOCK PURCHASE WARRANT JAGUAR HEALTH, INC. Warrant Shares: 1,304,545 Initial Exercise Date: December 9, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Iliad Research and Trading, L.P., a Utah limited partnership, or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the con |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 7, 2026 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT JAGUAR HEALTH, INC. PRE-FUNDED COMMON STOCK PURCHASE WARRANT JAGUAR HEALTH, INC. Warrant Shares: 304,827 Initial Exercise Date: December 12, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Iliad Research and Trading, L.P., a Utah limited partnership, or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the cond |
|
| April 7, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Jaguar Health, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share Other 348,827 $ 0.39 $ 136,042.53 0.0001381 $ 18.79 Total Offering Amou |
|
| April 7, 2026 |
As filed with the Securities and Exchange Commission on April 7, 2026 S-8 As filed with the Securities and Exchange Commission on April 7, 2026 Registration Statement No. |
|
| April 7, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. |
|
| April 7, 2026 |
Exhibit 19.1 JAGUAR ANIMAL HEALTH, INC. POLICY ON INSIDER TRADING AND TIPPING (to be effective upon the Company’s initial public offering) INTRODUCTION In the normal course of business, officers, directors and employees of Jaguar Animal Health, Inc. (“Company”) may come into possession of material nonpublic information. This information is considered the property of the Company. In particular, if |
|
| April 7, 2026 |
SUBSIDIARIES OF JAGUAR HEALTH, INC. Exhibit 21.1 SUBSIDIARIES OF JAGUAR HEALTH, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Napo Pharmaceuticals, Inc. Delaware Napo Therapeutics S.p.A. Italy |
|
| April 7, 2026 |
EX-99.1 Exhibit 99.1 Jaguar Health Reports 2025 Financials Net revenue increase of 5% in Q4 2025 vs. Q3 2025 Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 – Jaguar’s commercialized crofelemer drugs – with an additional $2 million due upon completion of post-closing conditions; |
|
| April 7, 2026 |
THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| April 1, 2026 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the |
|
| March 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| March 9, 2026 |
EX-10.1 Exhibit 10.1 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”), dated as of March 6, 2026 (the “Effective Date”), is executed by Napo Pharmaceuticals, Inc., a Delaware corporation (“Napo”), in favor of Streeterville Capital, LLC, a Utah limited liability company (“Secured Party”). A. Jaguar Health, Inc., Napo’s parent (“Jaguar” and together with Napo, the “Debtor”), has issued |
|
| March 9, 2026 |
EX-10.2 Exhibit 10.2 WARRANT TERMINATION AGREEMENT This WARRANT TERMINATION AGREEMENT (this “Agreement”) is made effective as of March 6, 2026 (the “Effective Date”), by and among each of the undersigned warrant holders (the “Holders”), and Jaguar Health, Inc., a Delaware corporation (“Company”). A. Company previously issued to Holders the Warrants to Purchase Common Stock described on Schedule 1 |
|
| March 9, 2026 |
AMENDMENT TO SECURED PROMISSORY NOTE EX-4.3 Exhibit 4.3 AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this “Amendment”) is entered into as of March 6, 2026, by and among Streeterville Capital, LLC, a Utah limited liability company (“Lender”), Jaguar Health, Inc., a Delaware corporation (“Company”), and Napo Pharmaceuticals, Inc., a Delaware corporation (“Napo”, and together with Company, “Borrower”). |
|
| March 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 9, 2026 |
EX-4.1 Exhibit 4.1 GLOBAL AMENDMENT #4 This Global Amendment #4 (this “Amendment”) is entered into as of March 6, 2026 by and between Uptown Capital, LLC, a Utah limited liability company (f/k/a Irving Park Capital, LLC) (“Investor”), and Jaguar Health, Inc. a Delaware corporation (“Company”). Capitalized terms used in this Amendment without definition shall have the meanings given to them in the |
|
| March 9, 2026 |
EX-4.2 Exhibit 4.2 GLOBAL AMENDMENT #4 This Global Amendment #4 (this “Amendment”) is entered into as of March 6, 2026 by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc., a Delaware corporation (“Company”). Capitalized terms used in this Amendment without definition shall have the meanings given to them in the Royalty Interest (as defi |
|
| March 9, 2026 |
AMENDMENT TO SECURED PROMISSORY NOTE EX-4.4 Exhibit 4.4 AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this “Amendment”) is entered into as of March 6, 2026, by and between Streeterville Capital, LLC, a Utah limited liability company (“Lender”), and Jaguar Health, Inc., a Delaware corporation (“Company” or “Borrower”). Capitalized terms used but not otherwise defined herein shall have the meanings asc |
|
| March 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 3, 2026 |
EX-3.1 Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES O CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of Jagu |
|
| March 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 18, 2026 |
EX-3.1 Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES O CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of Jagu |
|
| February 18, 2026 |
EX-99.1 Exhibit 99.1 Jaguar Health Announces a Special One-time Stock Dividend Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CA / February 18, 2026 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or “the Company”) today announced that its Board of Directors has declared a one-time special stock dividend (the “S |
|
| February 18, 2026 |
EX-99.2 Exhibit 99.2 Risk Factors Unless the context otherwise requires, references herein to “Jaguar,” the “Company,” “we,” “us,” and “our” refer to Jaguar Health, Inc. Terms used but not defined herein have the respective meanings set forth in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on February 18, 2026. (the “Current Report”). The risk factors discu |
|
| February 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 18, 2026 |
EX-4.1 Exhibit 4.1 [NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| January 23, 2026 |
THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| January 23, 2026 |
THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| January 23, 2026 |
THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| January 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 23, 2026 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT JAGUAR HEALTH, INC. Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT JAGUAR HEALTH, INC. Warrant Shares: [] Initial Exercise Date: January 16, 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [], or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| January 23, 2026 |
THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| January 23, 2026 |
THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| January 23, 2026 |
THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| January 15, 2026 |
Exhibit 10.2 Certain identified information marked as [****] has been excluded from this exhibit because it both (i) is not material and (ii) is the type that the Company treats as private or confidential. MANUFACTURING AND SUPPLY AGREEMENT BY AND BETWEEN NAPO PHARMACEUTICALS, INC. , WOODWARD SPECIALTY LLC and solely for the purposes of section 13.2, Future Pak, LLC Table of Contents Article 1 Def |
|
| January 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 15, 2026 |
Exhibit 10.1 Certain identified information marked as [****] has been excluded from this exhibit because it both (i) is not material and (ii) is the type that the Company treats as private or confidential. License Agreement Between Napo Pharmaceuticals, Inc., Woodward Specialty LLC, and solely for the purposes of section 4.1 and Article 6, Jaguar Health, Inc., d/b/a Jaguar Animal health and solely |
|
| January 15, 2026 |
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million • $18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions) • Up to additional $20M in milestone and other future payments • Future Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1 • Jaguar continues to be the manufacturer o |
|
| January 12, 2026 |
Exhibit 4.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. Pr |
|
| January 12, 2026 |
Exhibit 4.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. Pr |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 06, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 12, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 6, 2026 (the “Execution Date”), is entered into by and between Jaguar Health, Inc., a Delaware corporation, (the “Company”), and (including its successors and assigns, “Investor”). WHEREAS, the Company and Investor are executing and delivering this Agreement in reliance upon an exe |
|
| January 12, 2026 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| January 12, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 5, 2026 (the “Execution Date”), is entered into by and between Jaguar Health, Inc., a Delaware corporation, (the “Company”), and (including its successors and assigns, “Investor”). WHEREAS, the Company and Investor are executing and delivering this Agreement in reliance upon an exe |
|
| January 12, 2026 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporat |
|
| January 12, 2026 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| January 12, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 6, 2026 (the “Execution Date”), is entered into by and between Jaguar Health, Inc., a Delaware corporation, (the “Company”), and (including its successors and assigns, “Investor”). WHEREAS, the Company and Investor are executing and delivering this Agreement in reliance upon an exe |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2026 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 12, 2026 |
Exhibit 4.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. Pr |
|
| December 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 8, 2025 |
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders Jaguar CEO Lisa Conte presenting December 8, 2025 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to register Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the l |
|
| December 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 08, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 25, 2025 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-290702 1,980,827 Shares of Common Stock Issuable Upon the Exchange of Outstanding Shares of Series N Perpetual Preferred Stock 161,583 Shares of Common Stock 479,442 Shares of Common Stock Issuable Upon the Exercise of Outstanding Pre-Funded Warrant This prospectus relates to the resale of up to 2,621,852 shares of Jagua |
|
| November 24, 2025 |
November 24, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Jaguar Health, Inc. Registration Statement on Form S-3 File No. 333-290702 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Jaguar Health, Inc., a Delaware corporation (the “Regi |
|
| November 19, 2025 |
AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this “Amendment”) is entered into as of November 17, 2025, by and among Streeterville Capital, LLC, a Utah limited liability company (“Lender”), Jaguar Health, Inc. |
|
| November 19, 2025 |
GLOBAL AMENDMENT #3 COMPANY: INVESTOR: GLOBAL AMENDMENT #3 This Global Amendment #3 (this “Amendment”) is entered into as of November 17, 2025 by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc. |
|
| November 19, 2025 |
GLOBAL AMENDMENT #3 COMPANY: INVESTOR: GLOBAL AMENDMENT #3 This Global Amendment #3 (this “Amendment”) is entered into as of November 17, 2025 by and between Iliad Research and Trading, L. |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 19, 2025 |
THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| November 19, 2025 |
GLOBAL AMENDMENT #3 COMPANY: INVESTOR: GLOBAL AMENDMENT #3 This Global Amendment #3 (this “Amendment”) is entered into as of November 17, 2025 by and between Uptown Capital, LLC, a Utah limited liability company (f/k/a Irving Park Capital, LLC) (“Investor”), and Jaguar Health, Inc. |
|
| November 14, 2025 |
EX-10.1 Exhibit 10.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of November 12, 2025, is entered into by and between JAGUAR HEALTH, INC., a Delaware corporation (“Company”), and STREETERVILLE CAPITAL, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and Investor are executing and delivering this Agreement in relian |
|
| November 14, 2025 |
[Remainder of page intentionally left blank; signature page to follow] EX-10.3 Exhibit 10.3 GUARANTY This GUARANTY, made effective as of November 12, 2025, is given by JAGX Holdings, LLC, a Utah limited liability company (“Guarantor”), for the benefit of Streeterville Capital, LLC, a Utah limited liability company, and its successors, transferees, and assigns (collectively “Investor”). PURPOSE A. Jaguar Health, Inc., a Delaware corporation and parent of Guarantor (“C |
|
| November 14, 2025 |
EX-10.4 Exhibit 10.4 PLEDGE AGREEMENT This PLEDGE AGREEMENT (this “Agreement”) is entered into as of November 12, 2025, by and between Streeterville Capital, LLC, a Utah limited liability company (the “Secured Party”), and Jaguar Health, Inc., a Delaware corporation (the “Pledgor”). A. Effective as of the date hereof, the Secured Party purchased from Pledgor that certain Secured Promissory Note of |
|
| November 14, 2025 |
DEPOSIT ACCOUNT CONTROL AGREEMENT EX-10.2 Exhibit 10.2 DEPOSIT ACCOUNT CONTROL AGREEMENT This Deposit Account Control Agreement is made as of November 12, 2025, by and among Lakeside Bank, an Illinois banking corporation (the “Bank”), Streeterville Capital, LLC, a Utah limited liability company (the “Lender”), and JAGX Holdings, LLC, a Utah limited liability company (the “Guarantor”). WHEREAS, Lender has agreed to make a loan in t |
|
| November 14, 2025 |
SECURED PROMISSORY NOTE Effective Date: November 12, 2025 U.S. $10,810,000.00 EX-4.1 Exhibit 4.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREF |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission F |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Pro xy Sta tement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| October 10, 2025 |
X0708 D LIVE 0001585608 Jaguar Health, Inc. 200 Pine St., Ste 400 San Francisco CA CALIFORNIA 94104 415-371-8300 DELAWARE None Jaguar Animal Health, Inc. Corporation true Lisa Conte 200 Pine St., Ste 400 San Francisco CA CALIFORNIA 94104 Executive Officer Director Carol Lizak 200 Pine St., Ste 400 San Francisco CA CALIFORNIA 94104 Executive Officer Steven King 200 Pine St., Ste 400 San Francisco C |
|
| October 3, 2025 |
Calculation of Filing Fee Tables S-3 Jaguar Health, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial |
|
| October 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission |
|
| October 3, 2025 |
As filed with the Securities and Exchange Commission on October 3, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on October 3, 2025 Registration No. |
|
| October 1, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT JAGUAR HEALTH, INC. EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| October 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 1, 2025 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), is dated as of September 28, 2025 (the “Effective Date”), by and among Jaguar Health, Inc., a Delaware corporation (the “Company”), and Brown Stone Capital Limited (“Purchaser”). The Company and the Purchaser may be referred to herein collectively as the “Parties” and each individually as a “P |
|
| September 23, 2025 |
X0708 D LIVE 0001585608 Jaguar Health, Inc. 200 Pine St., Ste 400 San Francisco CA CALIFORNIA 94104 415-371-8300 DELAWARE None Jaguar Animal Health, Inc. Corporation true Lisa Conte 200 Pine St., Ste 400 San Francisco CA CALIFORNIA 94104 Executive Officer Director Carol Lizak 200 Pine St., Ste 400 San Francisco CA CALIFORNIA 94104 Executive Officer Steven King 200 Pine St., Ste 400 San Francisco C |
|
| September 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| September 11, 2025 |
EX-3.1 Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES N PERPETUAL PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of Jaguar |
|
| September 11, 2025 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), is dated as of September 9, 2025, by and among Jaguar Health, Inc., a Delaware corporation (the “Company”), and the purchasers listed on the Schedule of Purchasers attached hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. Subject to the terms and conditions set fort |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 19, 2025 |
EX-99.1 Exhibit 99.1 Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required tot |
|
| August 14, 2025 |
JAGUAR HEALTH, INC. Up to $3,378,239 Shares of Common Stock 424B5 Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 6 dated August 14, 2025 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $3,378,239 Shares of Common Stock This supplement No. 6 (this “Supplement) amends and supplements certain information contained in the prospectus supplement, dated May 23, 2024, and as amended by th |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 14, 2025 |
EX-10.1 Exhibit 10.1 August 14, 2025 Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Attn: Lisa A. Conte, President & CEO Dear Ms. Conte: Reference is made to the At The Market Offering Agreement, dated as of December 10, 2021 (the “ATM Agreement”), between Jaguar Health, Inc. (the “Company”) and Ladenburg Thalmann & Co., Inc. (the “Ladenburg”), as amended by way of letter a |
|
| August 6, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 30, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-288927 481,150 Shares of Common Stock Issuable Upon the Conversion of Outstanding Replacement Notes 928,582 Shares of Common Stock Issuable Upon the Exercise of Outstanding Common Warrants This prospectus relates to the resale of up to 1,409,732 shares of Jaguar Health, Inc. (the “Company,” “we,” “our” or “us”) voting common s |
|
| July 28, 2025 |
July 28, 2025 Lisa A. Conte Chief Executive Officer and President Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, California 94104 Re: Jaguar Health, Inc. Registration Statement on Form S-3 Filed July 24, 2025 File No. 333-288927 Dear Lisa A. Conte: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regar |
|
| July 28, 2025 |
CORRESP July 28, 2025 Via EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Jaguar Health, Inc. Registration Statement on Form S-3 File No. 333-288927 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Jaguar Health, Inc., a Delaware corporation (the “Registrant”), hereby requests the above-referenced Regis |
|
| July 24, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Jaguar Health, Inc. |
|
| July 24, 2025 |
As filed with the Securities and Exchange Commission on July 24, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on July 24, 2025 Registration No. |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a -6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| June 30, 2025 |
EX-3.1 Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES M PERPETUAL PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of Jaguar |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 30, 2025 |
Streeterville Series M Exchange Agreement. Exhibit 10.2 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of June 27, 2025 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc., a Delaware |
|
| June 30, 2025 |
Iliad Series M Exchange Agreement. Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of June 27, 2025 (the “Effective Date”) by and between Iliad Research and Trading, L.P., a Utah limited partnership (“Investor”), and Jaguar Health, Inc., a Delaware |
|
| June 27, 2025 |
JAGUAR HEALTH, INC. Up to $3,378,239 Shares of Common Stock Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 5 dated June 27, 2025 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $3,378,239 Shares of Common Stock This supplement No. 5 (this “Supplement) amends and supplements certain information contained in the prospectus supplement, dated May 23, 2024, and as amended by the supple |
|
| June 27, 2025 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-288202 492,612 Shares of Common Stock Issuable Upon the Exercise of Outstanding Common Warrants 14,778 Shares of Common Stock Issuable Upon the Exercise of Outstanding Placement Agent Warrants This prospectus relates to the resale of up to 507,390 shares of Jaguar Health, Inc. (the “Company,” “we,” “our” or “us”) voting |
|
| June 27, 2025 |
X0101 EFFECT 33 LIVE 2025-06-27 16:00:00 S-3 0001585608 Jaguar Health, Inc. 333-288202 |
|
| June 25, 2025 |
June 25, 2025 Via EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Jaguar Health, Inc. Registration Statement on Form S-3 File No. 333-288202 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Jaguar Health, Inc., a Delaware corporation (the “Registrant”), hereby requests the above-referenced Registration |
|
| June 25, 2025 |
June 25, 2025 Lisa Conte Chief Executive Officer Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Re: Jaguar Health, Inc. Registration Statement on Form S-3 Filed June 20, 2025 File No. 333-288202 Dear Lisa Conte: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accelerati |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| June 24, 2025 |
Exhibit 99.1 Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 Company’s CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing San Francisco, CA (June 24, 2025): Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or “t |
|
| June 24, 2025 |
Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECU |
|
| June 24, 2025 |
Form of Note Exchange and Warrant Purchase Agreement EXHIBIT 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(A)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. NOTE EXCHANGE AND WARRANT PURCHASE AGREEMENT THIS NOTE EXCHANGE AND WARRANT PURCHASE AGREEMENT (this “Agreement”), dated as of June 23, 2025 (the “Execution Date”), is entered into by and between JAGUAR HEALTH, INC., a Delaware corporation, (the “ |
|
| June 24, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| June 20, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Jaguar Health, Inc. |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| May 22, 2025 |
Form of Common Stock Purchase Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| May 22, 2025 |
Exhibit 99.1 Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules San Francisco, CA (May 21, 2025): Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or “the Company”), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct o |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 22, 2025 |
EX-4.2 3 d927226dex42.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX |
|
| May 22, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 20, 2025, between Jaguar Health, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set f |
|
| May 22, 2025 |
JAGUAR HEALTH, INC. 246,306 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-278861 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED MAY 1, 2024) JAGUAR HEALTH, INC. 246,306 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 246,306 shares of our voting common stock, $0.0001 par value per share (“Common Stock”), at an offering price of $6.09 per sha |
|
| May 21, 2025 |
JAGUAR HEALTH, INC. Up to $2,177,438 Shares of Common Stock 424B5 Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 4 dated May 21, 2025 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $2,177,438 Shares of Common Stock This supplement No. 4 (this “Supplement) amends and supplements certain information contained in the prospectus supplement, dated May 23, 2024, and as amended by the s |
|
| May 15, 2025 |
Exhibit 3.1 JAGUAR HEALTH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES L PERPETUAL PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, Lisa A. Conte and Carol R. Lizak, do hereby certify that: 1. They are the Chief Executive Officer/President and Chief Financial Officer, respectively, of Jaguar Health |
|
| May 15, 2025 |
Iliad Series L Exchange Agreement. Exhibit 10.3 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 14, 2025 (the “Effective Date”) by and between Iliad Research and Trading, L.P., a Utah limited partnership (“Investor”), and Jaguar Health, Inc., a Delaware c |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 15, 2025 |
EX-99.1 Exhibit 99.1 Jaguar Health Reports First Quarter 2025 Financials The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4 million and 37% versus net Q4 2024 revenue of $3.5 million Mytesi prescription volume increased by approximately 1.8% in Q1 202 |
|
| May 15, 2025 |
Iliad Common Stock Exchange Agreement. Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 13, 2025 (the “Effective Date”) by and between Iliad Research and Trading, L.P., a Utah limited partnership (“Lender”), and Jaguar Health, Inc., a Delaware cor |
|
| May 15, 2025 |
Exhibit 10.3 February 4, 2025 Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Attn: Lisa A. Conte, President & CEO Dear Ms. Conte: Reference is made to the At The Market Offering Agreement, dated as of December 10, 2021 (the “ATM Agreement”), between Jaguar Health, Inc. (the “Company”) and Ladenburg Thalmann & Co., Inc. (the “Ladenburg”), as amended by way of letter agreemen |
|
| May 15, 2025 |
Streeterville Exchange Agreement. Exhibit 10.2 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into as of May 14, 2025 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Jaguar Health, Inc., a Delaware c |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 9, 2025 |
Jaguar Health, Inc. (NASDAQ: JAGX) Overview – May 2025 Exhibit 99.1 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. (“Jaguar” or t |
|
| May 7, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-286550 631,922 Shares of Common Stock Issuable Upon the Conversion of Outstanding Notes 622,584 Shares of Common Stock Issuable Upon the Exercise of Outstanding Common Warrants 37,376 Shares of Common Stock Issuable Upon the Exercise of Outstanding Placement Agent Warrants This prospectus relates to the resale of up to 1,291,8 |
|
| May 5, 2025 |
CORRESP May 5, 2025 Via EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Jaguar Health, Inc. Registration Statement on Form S-3 File No. 333-286550 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Jaguar Health, Inc., a Delaware corporation (the “Registrant”), hereby requests the above-referenced Registr |
|
| May 5, 2025 |
EX-10.1 Exhibit 10.1 WAIVER This Waiver is entered into effective as of May 5, 2025, by and between Jaguar Health, Inc., a Delaware corporation (the “Company”), and each buyer identified on the signature pages hereto (each, including its successors and assigns, a “Buyer” and collectively, the “Buyers”), pursuant to that certain Securities Purchase Agreement, dated as of March 26, 2025, by and betw |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 5, 2025 |
JAGUAR HEALTH, INC. Up to $5,664,382 Shares of Common Stock Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 3 dated May 5, 2025 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $5,664,382 Shares of Common Stock This supplement No. 3 (this “Supplement”) amends and supplements certain information contained in the prospectus supplement, dated May 23, 2024, and as amended by the supplem |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 30, 2025 |
Exhibit 99.1 Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% – Potential to Modify Disease Progression in Intestinal Failure Patients Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results fr |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 28, 2025 |
About Crofelemer About the Jaguar Health Family of Companies Forward-Looking Statements Contact: Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and poss |
|
| April 28, 2025 |
FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 25, 2025 |
As filed with the Securities and Exchange Commission on April 25, 2025 Table of Contents As filed with the Securities and Exchange Commission on April 25, 2025 Registration No. |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 25, 2025 |
Jaguar Health, Inc. (NASDAQ: JAGX) Overview – April 2025 Jaguar Health, Inc. (NASDAQ: JAGX) Overview – April 2025 Forward-Looking Statements 2 This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. (“Jaguar” or the “Compa |
|
| April 25, 2025 |
Reed Smith LLP 599 Lexington Avenue New York, NY 10022 +212 521 5400 Fax +1 212 521 5450 reedsmith. |
|
| April 25, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 24, 2025 |
April 24, 2025 Lisa A. Conte Chief Executive Officer Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Re: Jaguar Health, Inc. Registration Statement on Form S-3 Filed April 15, 2025 File No. 333-286550 Dear Lisa A. Conte: We have conducted a limited review of your registration statement and have the following comment. Please respond to this letter by amending your registratio |
|
| April 21, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 21, 2025 |
Jaguar Health, Inc. (NASDAQ: JAGX) Overview – April 2025 Jaguar Health, Inc. (NASDAQ: JAGX) Overview – April 2025 Forward-Looking Statements 2 This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. (“Jaguar” or the “Compa |
|
| April 15, 2025 |
As filed with the Securities and Exchange Commission on April 15, 2025 As filed with the Securities and Exchange Commission on April 15, 2025 Registration Statement No. |
|
| April 15, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jaguar Health, Inc. |
|
| April 15, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Jaguar Health, Inc. |
|
| April 15, 2025 |
As filed with the Securities and Exchange Commission on April 15, 2025 Table of Contents As filed with the Securities and Exchange Commission on April 15, 2025 Registration No. |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| April 4, 2025 |
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules San Francisco, CA (April 1, 2025): Jaguar Health, Inc. |
|
| April 4, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 31, 2025 |
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023 The total net revenue for the year ended December 31, 2024 of approximately $11. |
|
| March 31, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF JAGUAR HEALTH, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Napo Pharmaceuticals, Inc. Delaware Napo Therapeutics S.p.A. Italy |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K Table of Contents d UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. |
|
| March 31, 2025 |
Jaguar Health, Inc. Insider Trading Policy. Exhibit 19.1 JAGUAR ANIMAL HEALTH, INC. POLICY ON INSIDER TRADING AND TIPPING (to be effective upon the Company’s initial public offering) INTRODUCTION In the normal course of business, officers, directors and employees of Jaguar Animal Health, Inc. (“Company”) may come into possession of material nonpublic information. This information is considered the property of the Company. In particular, if |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 26, 2025 |
SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 26, 2025, (the “Execution Date”), is entered into by and between Jaguar Health, Inc. |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 26, 2025 |
NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION ST |
|
| March 26, 2025 |
REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 26, 2025 (the “Execution Date”), is entered into by and between JAGUAR HEALTH, INC. |
|
| March 26, 2025 |
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3. |
|
| March 26, 2025 |
NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. |
|
| March 26, 2025 |
NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION ST |
|
| March 18, 2025 |
Jaguar Health, Inc. Announces Reverse Stock Split Reverse split approved at March 2025 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on March 24, 2025 San Francisco, CA (March 18, 2025): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced that the Company will effect a reverse stock split of its issued and o |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 18, 2025 |
CERTIFICATE OF NINTH AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JAGUAR HEALTH, INC. |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 13, 2025 |
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer San Francisco, CA (March 13, 2025): Jaguar Health, Inc. |
|
| February 27, 2025 |
Jaguar Health, Inc. and EQUINITI TRUST COMPANY, LLC, as Rights Agent RIGHTS AGREEMENT Dated as of February 26, 2025 TABLE OF CONTENTS Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 8 Section 3. Issue of Right Certificates. 8 Section 4. Form of Right Certificates 10 Section 5. Countersignature and Registration. 11 Section 6. Transfer, Split Up, Combination and Exchange |
|
| February 27, 2025 |
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer Jaguar has received an indication of interest to acquire the Company SAN FRANCISCO, CA / February 27, 2025 / Jaguar Health, Inc. |
|
| February 27, 2025 |
CERTIFICATE OF DESIGNATION of SERIES K JUNIOR PARTICIPATING PREFERRED STOCK of Jaguar Health, Inc. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 jaguar health, Inc. (Exact name of registrant as specified in its charter) Delaware 46-2956775 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 20 |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| February 20, 2025 |
AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this “Amendment”) is entered into as of February 13, 2025, by and among Streeterville Capital, LLC, a Utah limited liability company (“Lender”), Jaguar Health, Inc. |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 4, 2025 |
EX-4.1 Exhibit 4.1 AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this “Amendment”) is entered into as of January 29, 2025, by and among Streeterville Capital, LLC, a Utah limited liability company (“Lender”), Jaguar Health, Inc., a Delaware corporation (“Company”), and Napo Pharmaceuticals, Inc., a Delaware corporation (“Napo”, and together with Company, “Borrower |
|
| January 29, 2025 |
JAGX / Jaguar Health, Inc. / Uptown Capital, LLC Passive Investment SCHEDULE 13G 0001978034 XXXXXXXX LIVE Common stock, Par Value $0.0001 Per Share 01/29/2025 0001585608 Jaguar Health, Inc. 47010C805 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 Rule 13d-1(c) John Fife and Fredrick Waid X1 1290000.00 0.00 1290000.00 0.00 1290000.00 9.9 IN *John Fife has sole voting and dispositive power over 1,290,000 shares. ** 12,900 shares owned on behalf of John Fife; 1,277 |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 13, 2024 |
Exhibit 99.1 Jaguar Health Reports Third Quarter 2024 Financial Results The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million Jaguar reported significant results in breast cancer patients in its |
|
| November 13, 2024 |
Exhibit 10.1 November 13, 2024 Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Attn: Lisa A. Conte, President & CEO Dear Ms. Conte: Reference is made to the At The Market Offering Agreement, dated as of December 10, 2021 (the “ATM Agreement”), between Jaguar Health, Inc. (the “Company”) and Ladenburg Thalmann & Co., Inc. (the “Ladenburg”), as amended by way of letter agreeme |
|
| November 13, 2024 |
JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 2 dated November 13, 2024 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock This supplement No. 2 amends, supplements or modifies certain information contained in the prospectus supplement, dated May 23, 2024 and as amended by the supplement N |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 13, 2024 |
As filed with the Securities and Exchange Commission on August 13, 2024 As filed with the Securities and Exchange Commission on August 13, 2024 Registration Statement No. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 13, 2024 |
Exhibit 99.1 Jaguar Health Reports Second Quarter 2024 Financial Results The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million Company to complete analysis of full data for first and second 12-week periods of pivotal p |
|
| August 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jaguar Health, Inc. |
|
| August 13, 2024 |
Third Amendment to the Jaguar Health, Inc. New Employee Inducement Award Plan.* Exhibit 99.4 Jaguar Health, INC. THIRD AMENDMENT TO 2020 New Employee Inducement Award PLAN (Effective August 13, 2024) Jaguar Health, Inc., a Delaware corporation (the “Company”), hereby adopts this Third Amendment (this “Amendment”) to the 2020 New Employee Inducement Award Plan (as amended, the “Plan”). WITNESSETH WHEREAS, the Company’s Board of Directors (the “Board”) has adopted the Plan; WHE |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| July 23, 2024 |
Exhibit 99.1 Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer |
|
| July 22, 2024 |
JAGX / Jaguar Health, Inc. / Iliad Research & Trading, L.P. - 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Jaguar Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 47010C805 (CUSIP Number) John Fife, 303 E Wacker Dr, Suite 1040 Chicago, IL 60601 (Name, Address and Telephone Number of Person Authorized to |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| July 18, 2024 |
Exhibit 10.1 July 17, 2024 Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Attn: Lisa A. Conte, President & CEO Dear Ms. Conte: Reference is made to the At The Market Offering Agreement, dated as of December 10, 2021 (the “ATM Agreement”), between Jaguar Health, Inc. (the “Company”) and Ladenburg Thalmann & Co., Inc. (the “Ladenburg”), as amended by way of letter agreements |
|
| July 18, 2024 |
JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) File No. 333-278861 Supplement No. 1 dated July 17, 2024 To Prospectus Supplement dated May 23, 2024 (To Prospectus Dated May 1, 2024) JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock This supplement amends, supplements or modifies certain information contained in the prospectus supplement, dated May 23, 2024 (the “ATM Prospectus Supplement”), and the a |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| June 26, 2024 |
Exhibit 99.1 Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement JAGX’s securities continue to be listed and traded on Nasdaq Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 San Francisco, CA (June 26, 2024): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced that on June |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File |
|
| June 21, 2024 |
Exhibit 99.1 Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 Investor webcast on or before July 23 will include updates on Jaguar’s cancer supportive care portfolio, including participation from Jaguar scientific team, patient |
|
| June 10, 2024 |
US47010C6075 / Jaguar Health Inc / Iliad Research & Trading, L.P. - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jaguar Health, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 47010C805 (CUSIP Number) June 10, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 28, 2024 |
200PineStreet,Suite400,SanFrancisco,CA94104 Tel:415.371.8300•Fax:415.371.8311 https://jaguar.health May21,2024 DearStockholder: Youarecordiallyinvitedtoattendthe2024AnnualMeetingof Stockholders(the“AnnualMeeting”) of JaguarHealth,Inc.(the“Company”)tobeheldat200PineStreet,Suite400,SanFrancisco,CA94104, onFriday,June21,2024,at8:30a.m.,localtime. AttheAnnualMeetingyouwillbeaskedto(i)electone(1)ClassI |
|
| May 23, 2024 |
Exhibit 3.1 CERTIFICATE OF EIGHTH AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JAGUAR HEALTH, INC. Jaguar Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that: 1. The name of the Corporation is Jaguar Health, Inc. The date of filing of the Corporation’s original Certificate o |
|
| May 23, 2024 |
Exhibit 99.1 Jaguar Health, Inc. Announces Reverse Stock Split Reverse split approved at April 2024 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 San Francisco, CA (May 17, 2024): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced that the Company will effect a reverse stock split of its iss |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-36714 46-2956775 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 23, 2024 |
JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-278861 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED MAY 1, 2024) JAGUAR HEALTH, INC. Up to $75,000,000 Shares of Common Stock We have entered into a sales agreement, dated December 10, 2021, as amended on February 2, 2022 and May 23, 2024 (the “ATM Agreement”), with Ladenburg Thalmann & Co. Inc. (“Ladenburg”) relating to share |
|
| May 23, 2024 |
Exhibit 10.1 May 23, 2024 Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco, CA 94104 Attn: Lisa A. Conte, President & CEO Dear Ms. Conte: Reference is made to the At The Market Offering Agreement, dated as of December 10, 2021 (the “ATM Agreement”), between Jaguar Health, Inc. (the “Company”) and Ladenburg Thalmann & Co., Inc. (the “Ladenburg”), as amended by way of letter agreement da |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
